Tower Bridge, London, United Kingdom

Portfolio

Our portfolio is managed according to industry standards, lowering execution risks while maximizing value creation and the chances of commercial success.

Our Programs

Discover more about the different programs.

 
Program

GPR120

GPR120 (FFAR4) AGONIST

Treatment of metabolic diseases

Discover the project
Program

NEO1940

CANNABINOID CB1/CB2 AGONIST

Multimodal supportive care therapy in cancer patients

Discover the project
Program

NEO6860

TRPV1 ANTAGONIST

Treatment of osteoarthritis, neuropathic, and visceral pain

Discover the project
Program

NEO5937

P2X3 RECEPTOR ANTAGONIST

Treatment of pain and respiratory indications

Discover the project
Program

NEO8877

TYPE 2 TRANSMEMBRANE SERINE PROTEASE (TTSP) INHIBITORS

Inhibitor against influenza

Discover the project
Program

NEO2734

BRD4 INHIBITOR

Bromodomain inhibitor against cancer

Discover the project
Program

HSP90

HSP90 MODULATOR

Development of a novel infarct-sparing agent

Discover the project
Program

PARG

PARG INHIBITOR

Repress cancer growth and sensitize cancer cells to DNA damage therapy

 

Discover the project
© 2017 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia